The field of cancer immunotherapy, where treatments are used to help a patient’s immune system find
and kill cancer cells, has transformed cancer care. Dedicated to raising awareness and education of this field, June is now celebrated by many cancer research organisations and groups as ‘Cancer Immunotherapy Month’.
To mark this occasion, here we summarise the plain language summaries of publications in immunotherapy published in Future Oncology.
Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer
Dostarlimab is a new type of treatment for women with recurrent or advanced endometrial cancer. The drug was approved for treatment based on the findings of a clinical study called GARNET, originally published in JAMA Oncology. This plain language summary can helps patients and other people affected by endometrial cancer understand the results of the GARNET study.
Read the article in full here.
A plain language summary from pembrolizumab plus ipilimumab following PD-1 antibody failure in melanoma
A new plain language summary discussing the results of a clinical study that looked at the use of two immunotherapy drugs, pembrolizumab and ipilimumab, for the treatment of advanced melanoma.
Read the full article here.
Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer
This new plain language summary explains the results of the JAVELIN Bladder 100 study which was originally published in the New England Journal of Medicine. The study was carried out to investigate the use of avelumab as maintenance treatment for people with advanced urothelial cancer whose cancer has shrunk or not grown with first-line chemotherapy
Read the summary here.
